eFFECTOR Therapeutics EFTR Stock
eFFECTOR Therapeutics Price Chart
eFFECTOR Therapeutics EFTR Financial and Trading Overview
| eFFECTOR Therapeutics stock price | 2.08 USD |
| Previous Close | 1.15 USD |
| Open | 1.12 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 900 |
| Day's Range | 0.9 - 1.13 USD |
| 52 Week Range | 0.34 - 1.99 USD |
| Volume | 4.96M USD |
| Avg. Volume | 1.8M USD |
| Market Cap | 56.05M USD |
| Beta (5Y Monthly) | 0.359823 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.37 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 USD |
EFTR Valuation Measures
| Enterprise Value | 50.1M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.98421055 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 15.776631 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 14.101 |
| Enterprise Value/EBITDA | -1.419 |
Trading Information
eFFECTOR Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.359823 |
| 52-Week Change | -37.24% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.99 USD |
| 52 Week Low | 0.34 USD |
| 50-Day Moving Average | 0.67 USD |
| 200-Day Moving Average | 0.55 USD |
EFTR Share Statistics
| Avg. Volume (3 month) | 1.8M USD |
| Avg. Daily Volume (10-Days) | 4.17M USD |
| Shares Outstanding | 59.95M |
| Float | 27.48M |
| Short Ratio | 0.44 |
| % Held by Insiders | 7.90% |
| % Held by Institutions | 64.03% |
| Shares Short | 1.24M |
| Short % of Float | 4.03% |
| Short % of Shares Outstanding | 2.64% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -996.087% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.93% |
| Return on Equity (ttm) | -350.10% |
Income Statement
| Revenue (ttm) | 3.55M USD |
| Revenue Per Share (ttm) | 0.09 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -19760000 USD |
| EBITDA | -35315000 USD |
| Net Income Avi to Common (ttm) | -35748000 USD |
| Diluted EPS (ttm) | -0.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 19.01M USD |
| Total Cash Per Share (mrq) | 0.45 USD |
| Total Debt (mrq) | 20.35M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.784 |
| Book Value Per Share (mrq) | -0.114 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27039000 USD |
| Levered Free Cash Flow (ttm) | -13856125 USD |
Profile of eFFECTOR Therapeutics
| Country | United States |
| State | CA |
| City | Solana Beach |
| Address | 142 North Cedros Avenue |
| ZIP | 92075 |
| Phone | 858 925 8215 |
| Website | https://effector.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Q&A For eFFECTOR Therapeutics Stock
What is a current EFTR stock price?
eFFECTOR Therapeutics EFTR stock price today per share is 2.08 USD.
How to purchase eFFECTOR Therapeutics stock?
You can buy EFTR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for eFFECTOR Therapeutics?
The stock symbol or ticker of eFFECTOR Therapeutics is EFTR.
Which industry does the eFFECTOR Therapeutics company belong to?
The eFFECTOR Therapeutics industry is Biotechnology.
How many shares does eFFECTOR Therapeutics have in circulation?
The max supply of eFFECTOR Therapeutics shares is 3.69M.
What is eFFECTOR Therapeutics Price to Earnings Ratio (PE Ratio)?
eFFECTOR Therapeutics PE Ratio is now.
What was eFFECTOR Therapeutics earnings per share over the trailing 12 months (TTM)?
eFFECTOR Therapeutics EPS is -16.37 USD over the trailing 12 months.
Which sector does the eFFECTOR Therapeutics company belong to?
The eFFECTOR Therapeutics sector is Healthcare.
eFFECTOR Therapeutics EFTR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}